Project Description

Author: Alam et al.


To compare the effects of probiotics supplementation on liver stiffness and steatosis in obese and non-obese patients with NAFLD.

The Pragmatic clinical trial included 50 obese (BMI ≥25 kg/m2) and 50 non-obese NAFLD (BMI <25 kg/m2) patients with proper consent procedure. Fibroscan with Controlled Attenuated Parameter (CAP) was done at day 0 and at the end of 6 months. Probiotics supplementation was provided for both groups for 6 months along with other standard management. Current declaration of Helsinki was strictly followed.

At inclusion, both groups had comparable characteristics except BMI, metabolic syndrome and WC (cm) (p<0.05). Beneficial changes occurred in BMI, WC, ALT, TC, LDL and TG levels of obese group (P=0.05 for all), and in SBP and LDL level in non-obese group. No significant change was observed in other liver enzymes and glycemic profiles. Significant improvement in CAP was observed at 6 months in both groups. But after adjusting for changes in BMI and WC, change in liver stiffness score (P<0.5) among obese participants was significant compared to non-obese ones.

Supplementation with probiotics may improve CAP in NAFLD patients irrespective of BMI with significantly higher improvement in liver stiffness among obese than that of non-obese patients.

Key words: NASH, NAFLD, Lean NASH, Steatohepatitis, Non-obese NASH, Probiotics

Status: Ongoing

Full text link: Not available